Entrectinib is an investigational therapy designed to target specific causes of certain types of cancer, specifically rearrangements or “fusions” of the NTRK1, NTRK2, NTRK3, ROS1, and ALK genes (visit Ignyta.com to learn more about the relationship between gene fusions and cancer formation).
Ignyta’s STARTRK-2 trial of entrectinib is now recruiting patients with fusions of the ROS1, ALK, and NTRK genes. Your doctor can order a no-cost test to see if your cancer has these gene fusions, and if you are a candidate for the STARTRK-2 clinical trial. This test, in most cases, can be performed on a tumor sample that was previously obtained and stored, avoiding the need for a new biopsy.
Learn What to Expect Along the Way
Navigating life after a cancer diagnosis can be overwhelming and stressful. There are many unknown factors and many critical decisions, all demanding attention. We want you to make a confident decision about whether to consider enrollment in STARTRK-2.
Here are some points to consider:
This clinical trial will evaluate the potential response of tumors with specific gene fusions to an investigational drug called entrectinib.
Adults with various types of cancer are invited to check their eligibility with our no-cost diagnostic test. Learn more if your diagnosis may make you eligible to participate.
Participants in the trial will be followed closely by a team of experts. Any side effects will be thoroughly evaluated and addressed.
Have you or someone you care for been diagnosed with one of the following cancer types?
- Lung (NSCLC)
- Gastrointestinal (GI) and Colorectal Cancer (CRC)
- Gastrointestinal Stomal Tumors (GIST)
- Head and Neck